An elevated CD8/FOXP3 ratio emerges as a notable prognostic indicator for enhanced survival across diverse cancer types, including rectal cancer, esophageal squamous cell cancer, lung adenocarcinoma and cervical cancer [9, 31–33]. This evidence concerns the gene FOXP3 and rectal cancer.